NEW YORK (GenomeWeb News) - Investment firm Caris & Company upgraded Illumina's stock to "Buy" from "Above Average" today.
The broker cited "removal of Markman ruling overhang" as the reason behind the upgrade.
Separately today, investment bank UBS lifted Affymetrix' price target to $20 from $18.
As GenomeWeb News reported this morning, a district court judge issued a Markman order to interpret 15 key terms in Affymetrix’ patent infringement case against Illumina.
Shares in Affy were down 4.51 percent, or $1, at $21.13 in mid-afternoon trading while shares in Illumina were up 3.67 percent, or $1.17, at 32.98.